Which has preferable earnings & valuation, AGEN or ANAB?

Agenus has higher earnings, but lower revenue than AnaptysBio. Agenus is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agenus $114.20M 3.31 $120K $2.58 3.24 AnaptysBio $232.39M 6.24 -$13.23M $5.37 9.04

Is AGEN or ANAB more profitable?

AnaptysBio has a net margin of 82.37% compared to Agenus' net margin of 69.33%. AnaptysBio's return on equity of 112.00% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 69.33% -47.68% 57.73% AnaptysBio 82.37% 112.00% 2.20%

Does the media refer more to AGEN or ANAB?

In the previous week, Agenus and Agenus both had 10 articles in the media. Agenus' average media sentiment score of 0.48 beat AnaptysBio's score of 0.02 indicating that Agenus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral AnaptysBio 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AGEN or TSHA?

In the previous week, Agenus had 7 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 10 mentions for Agenus and 3 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.55 beat Agenus' score of 0.48 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, INBX or AGEN?

Agenus has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inhibrx Biosciences $1.30M 1,098.23 -$140.05M -$8.88 N/A Agenus $114.20M 3.31 $120K $2.58 3.24

Is INBX or AGEN more profitable?

Agenus has a net margin of 69.33% compared to Inhibrx Biosciences' net margin of 0.00%. Agenus' return on equity of -47.68% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -83.48% Agenus 69.33% -47.68% 57.73%

Does the media favor INBX or AGEN?

In the previous week, Inhibrx Biosciences had 1 more articles in the media than Agenus. MarketBeat recorded 11 mentions for Inhibrx Biosciences and 10 mentions for Agenus. Inhibrx Biosciences' average media sentiment score of 0.98 beat Agenus' score of 0.48 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agenus 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, AGEN or KLRA?

Agenus has higher revenue and earnings than Kailera Therapeutics. Kailera Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agenus $114.20M 3.31 $120K $2.58 3.24 Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A

Does the media favor AGEN or KLRA?

In the previous week, Agenus had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 10 mentions for Agenus and 9 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.48 beat Agenus' score of 0.48 indicating that Kailera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Kailera Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, AGEN or OMER?

Agenus has higher revenue and earnings than Omeros. Agenus is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agenus $114.20M 3.31 $120K $2.58 3.24 Omeros N/A N/A -$3.35M $1.28 14.54

Is AGEN or OMER more profitable?

Agenus has a net margin of 69.33% compared to Omeros' net margin of 0.00%. Agenus' return on equity of -47.68% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 69.33% -47.68% 57.73% Omeros N/A -164.92% 69.41%

Does the media favor AGEN or OMER?

In the previous week, Agenus had 7 more articles in the media than Omeros. MarketBeat recorded 10 mentions for Agenus and 3 mentions for Omeros. Omeros' average media sentiment score of 0.67 beat Agenus' score of 0.48 indicating that Omeros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Omeros 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Agenus (AGEN) Competitors

$8.36 +0.03 (+0.36%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$8.38 +0.02 (+0.24%)

As of 10/2/2026 07:58 PM Eastern

Compare

AGEN vs. ANAB, TSHA, INBX, KLRA, and OMER

Should you buy Agenus stock or one of its competitors? Agenus's main competitors and comparable companies include AnaptysBio (ANAB), Taysha Gene Therapies (TSHA), Inhibrx Biosciences (INBX), Kailera Therapeutics (KLRA), and Omeros (OMER). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Agenus compare to AnaptysBio?

Agenus (NASDAQ:AGEN) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

AnaptysBio has a net margin of 82.37% compared to Agenus' net margin of 69.33%. AnaptysBio's return on equity of 112.00% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
AnaptysBio	82.37%	112.00%	2.20%

In the previous week, Agenus and Agenus both had 10 articles in the media. Agenus' average media sentiment score of 0.48 beat AnaptysBio's score of 0.02 indicating that Agenus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
AnaptysBio	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agenus has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Agenus presently has a consensus price target of $24.50, indicating a potential upside of 193.06%. AnaptysBio has a consensus price target of $77.79, indicating a potential upside of 60.28%. Given Agenus' higher probable upside, equities research analysts plainly believe Agenus is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

61.5% of Agenus shares are owned by institutional investors. 6.5% of Agenus shares are owned by company insiders. Comparatively, 31.5% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Agenus has higher earnings, but lower revenue than AnaptysBio. Agenus is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	3.31	$120K	$2.58	3.24
AnaptysBio	$232.39M	6.24	-$13.23M	$5.37	9.04

Summary

AnaptysBio beats Agenus on 9 of the 15 factors compared between the two stocks.

How does Agenus compare to Taysha Gene Therapies?

Agenus (NASDAQ:AGEN) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, Agenus had 7 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 10 mentions for Agenus and 3 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.55 beat Agenus' score of 0.48 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.5% of Agenus shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 6.5% of Agenus shares are held by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Agenus has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	3.31	$120K	$2.58	3.24
Taysha Gene Therapies	$9.77M	154.41	-$109M	-$0.42	N/A

Agenus has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market.

Agenus has a net margin of 69.33% compared to Taysha Gene Therapies' net margin of 0.00%. Agenus' return on equity of -47.68% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

Agenus presently has a consensus target price of $24.50, indicating a potential upside of 193.06%. Taysha Gene Therapies has a consensus target price of $12.77, indicating a potential upside of 175.79%. Given Agenus' higher probable upside, analysts clearly believe Agenus is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Agenus beats Taysha Gene Therapies on 11 of the 17 factors compared between the two stocks.

How does Agenus compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Agenus (NASDAQ:AGEN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Agenus has a net margin of 69.33% compared to Inhibrx Biosciences' net margin of 0.00%. Agenus' return on equity of -47.68% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
Agenus	69.33%	-47.68%	57.73%

In the previous week, Inhibrx Biosciences had 1 more articles in the media than Agenus. MarketBeat recorded 11 mentions for Inhibrx Biosciences and 10 mentions for Agenus. Inhibrx Biosciences' average media sentiment score of 0.98 beat Agenus' score of 0.48 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agenus	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Agenus has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,098.23	-$140.05M	-$8.88	N/A
Agenus	$114.20M	3.31	$120K	$2.58	3.24

Inhibrx Biosciences currently has a consensus price target of $197.50, indicating a potential upside of 103.63%. Agenus has a consensus price target of $24.50, indicating a potential upside of 193.06%. Given Agenus' higher possible upside, analysts plainly believe Agenus is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Agenus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Inhibrx Biosciences has a beta of 3.81, meaning that its stock price is 281% more volatile than the broader market. Comparatively, Agenus has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 6.5% of Agenus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Agenus beats Inhibrx Biosciences on 9 of the 16 factors compared between the two stocks.

How does Agenus compare to Kailera Therapeutics?

Agenus (NASDAQ:AGEN) and Kailera Therapeutics (NASDAQ:KLRA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Agenus has higher revenue and earnings than Kailera Therapeutics. Kailera Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	3.31	$120K	$2.58	3.24
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

In the previous week, Agenus had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 10 mentions for Agenus and 9 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.48 beat Agenus' score of 0.48 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kailera Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agenus has a net margin of 69.33% compared to Kailera Therapeutics' net margin of 0.00%. Kailera Therapeutics' return on equity of 0.00% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
Kailera Therapeutics	N/A	N/A	N/A

Agenus currently has a consensus price target of $24.50, suggesting a potential upside of 193.06%. Kailera Therapeutics has a consensus price target of $42.75, suggesting a potential upside of 311.45%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kailera Therapeutics is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

61.5% of Agenus shares are owned by institutional investors. 6.5% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Agenus beats Kailera Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Agenus compare to Omeros?

Agenus (NASDAQ:AGEN) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Agenus presently has a consensus price target of $24.50, suggesting a potential upside of 193.06%. Omeros has a consensus price target of $34.00, suggesting a potential upside of 82.70%. Given Agenus' higher probable upside, equities analysts plainly believe Agenus is more favorable than Omeros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Omeros	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Agenus had 7 more articles in the media than Omeros. MarketBeat recorded 10 mentions for Agenus and 3 mentions for Omeros. Omeros' average media sentiment score of 0.67 beat Agenus' score of 0.48 indicating that Omeros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agenus has a net margin of 69.33% compared to Omeros' net margin of 0.00%. Agenus' return on equity of -47.68% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
Omeros	N/A	-164.92%	69.41%

Agenus has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Omeros has a beta of 2.57, meaning that its share price is 157% more volatile than the broader market.

61.5% of Agenus shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 6.5% of Agenus shares are owned by insiders. Comparatively, 10.5% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Agenus has higher revenue and earnings than Omeros. Agenus is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	3.31	$120K	$2.58	3.24
Omeros	N/A	N/A	-$3.35M	$1.28	14.54

Summary

Agenus beats Omeros on 9 of the 16 factors compared between the two stocks.

Get Agenus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGEN vs. The Competition

Export

Metric	Agenus	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$376.20M	$3.87B	$7.14B	$13.18B
Dividend Yield	N/A	3.64%	2.53%	16.77%
P/E Ratio	3.24	13.06	274.83	26.04
Price / Sales	3.31	1,297.71	616.61	84.99
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	-1.02	16.63	10.93	6.31
Net Income	$120K	-$22.71M	$3.51B	$362.16M
7 Day Performance	-2.11%	-2.98%	-2.00%	-1.66%
1 Month Performance	1.46%	-10.59%	-6.15%	-4.50%
1 Year Performance	101.93%	19.46%	7.45%	2.06%

Agenus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGEN Agenus	3.186 of 5 stars	$8.36 +0.4%	$24.50 +193.1%	+112.2%	$376.20M	$114.20M	3.24	81	News Coverage
ANAB AnaptysBio	3.4425 of 5 stars	$50.80 -0.4%	$79.15 +55.8%	+54.9%	$1.52B	$234.60M	9.46	104	News Coverage Analyst Forecast Insider Trade
TSHA Taysha Gene Therapies	2.5403 of 5 stars	$4.99 +6.9%	$12.77 +155.9%	-5.1%	$1.52B	$9.77M	N/A	99	News Coverage Positive News Gap Up
INBX Inhibrx Biosciences	3.9038 of 5 stars	$101.71 +2.1%	$197.50 +94.2%	+176.6%	$1.47B	$1.30M	N/A	110
KLRA Kailera Therapeutics	2.5666 of 5 stars	$11.12 -0.9%	$42.75 +284.4%	N/A	$1.45B	N/A	N/A	145	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGEN) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agenus (AGEN) Competitors

AGEN vs. ANAB, TSHA, INBX, KLRA, and OMER

How does Agenus compare to AnaptysBio?

Summary

How does Agenus compare to Taysha Gene Therapies?

Summary

How does Agenus compare to Inhibrx Biosciences?

Summary

How does Agenus compare to Kailera Therapeutics?

Summary

How does Agenus compare to Omeros?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agenus (AGEN) Competitors

AGEN vs. ANAB, TSHA, INBX, KLRA, and OMER

How does Agenus compare to AnaptysBio?

Is AGEN or ANAB more profitable?

Does the media refer more to AGEN or ANAB?

Which has more volatility & risk, AGEN or ANAB?

Do analysts prefer AGEN or ANAB?

Do institutionals & insiders believe in AGEN or ANAB?

Which has preferable earnings & valuation, AGEN or ANAB?

Summary

How does Agenus compare to Taysha Gene Therapies?

Does the media refer more to AGEN or TSHA?

Do insiders & institutionals believe in AGEN or TSHA?

Which has better valuation and earnings, AGEN or TSHA?

Which has more volatility & risk, AGEN or TSHA?

Is AGEN or TSHA more profitable?

Do analysts rate AGEN or TSHA?

Summary

How does Agenus compare to Inhibrx Biosciences?

Is INBX or AGEN more profitable?

Does the media favor INBX or AGEN?

Which has preferable valuation & earnings, INBX or AGEN?

Do analysts prefer INBX or AGEN?

Which has more volatility & risk, INBX or AGEN?

Do insiders and institutionals hold more shares of INBX or AGEN?

Summary

How does Agenus compare to Kailera Therapeutics?

Which has preferable earnings and valuation, AGEN or KLRA?

Does the media favor AGEN or KLRA?

Is AGEN or KLRA more profitable?

Do analysts prefer AGEN or KLRA?

Do insiders & institutionals hold more shares of AGEN or KLRA?

Summary

How does Agenus compare to Omeros?

Do analysts rate AGEN or OMER?

Does the media favor AGEN or OMER?

Is AGEN or OMER more profitable?

Which has more volatility & risk, AGEN or OMER?

Do insiders & institutionals have more ownership in AGEN or OMER?

Which has preferable earnings & valuation, AGEN or OMER?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools